Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Utvärdering av effekt och säkerhet av Belantamab Mafodotin, Bortezomib och Dexametason kontra Daratumumab, Bortezomib och Dexametason hos deltagare med återfall/refraktärt multipelt myelom (DREAMM 7)

29 oktober 2026 uppdaterad av: GlaxoSmithKline

DRÖM 7: En multicenter, öppen etikett, randomiserad fas III-studie för att utvärdera effektiviteten och säkerheten av kombinationen av Belantamab Mafodotin, Bortezomib och Dexametason (B-Vd) jämfört med kombinationen av Daratumumab, Bortezomib och Dexametason (D-Vdadason) ) hos deltagare med återfall/refraktärt multipelt myelom

This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Faktisk)

494

Fas

  • Fas 3

Utökad åtkomst

Godkänd till försäljning till allmänheten. Se utökad åtkomstpost.

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • New South Wales
      • Camperdown, New South Wales, Australien, 2050
        • GSK Investigational Site
      • Liverpool, New South Wales, Australien, 2170
        • GSK Investigational Site
      • Newcastle, New South Wales, Australien, 2298
        • GSK Investigational Site
      • St Leonards, New South Wales, Australien, 2065
        • GSK Investigational Site
      • Wollongong, New South Wales, Australien, 2500
        • GSK Investigational Site
    • Queensland
      • Benowa, Queensland, Australien, 4217
        • GSK Investigational Site
      • Herston, Queensland, Australien, 4029
        • GSK Investigational Site
    • South Australia
      • Ashford, South Australia, Australien, 5037
        • GSK Investigational Site
    • Victoria
      • Box Hill, Victoria, Australien, 3128
        • GSK Investigational Site
      • Heidelberg, Victoria, Australien, 3084
        • GSK Investigational Site
      • Melbourne, Victoria, Australien, 3004
        • GSK Investigational Site
    • Western Australia
      • Murdoch, Western Australia, Australien, 6150
        • GSK Investigational Site
      • Nedlands, Western Australia, Australien, 6009
        • GSK Investigational Site
      • Roeselare, Belgien, 8800
        • GSK Investigational Site
    • Brussels Capital
      • Jette, Brussels Capital, Belgien, 1090
        • GSK Investigational Site
      • Woluwé-Saint-Lambert, Brussels Capital, Belgien, 1200
        • GSK Investigational Site
    • Oost-Vlaanderen
      • Ghent, Oost-Vlaanderen, Belgien, 9000
        • GSK Investigational Site
      • Joinville, Brasilien, 89201-260
        • GSK Investigational Site
      • Natal, Brasilien, 59075-740
        • GSK Investigational Site
      • Rio de Janeiro, Brasilien, 22775001
        • GSK Investigational Site
      • São Paulo, Brasilien, 04537-080
        • GSK Investigational Site
      • São Paulo, Brasilien, 05403-000
        • GSK Investigational Site
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasilien, 90035-903
        • GSK Investigational Site
    • Santa Catarina
      • Florianópolis, Santa Catarina, Brasilien, 88020-210
        • GSK Investigational Site
      • Amiens, Frankrike, 80054
        • GSK Investigational Site
      • Caen, Frankrike, 14033
        • GSK Investigational Site
      • Nice, Frankrike, 06200
        • GSK Investigational Site
      • Paris, Frankrike, 75651
        • GSK Investigational Site
      • Rennes, Frankrike, 35033
        • GSK Investigational Site
    • Arizona
      • Yuma, Arizona, Förenta staterna, 85364
        • GSK Investigational Site
    • Kansas
      • Mission, Kansas, Förenta staterna, 66205-2005
        • GSK Investigational Site
    • North Carolina
      • Denver, North Carolina, Förenta staterna, 80128
        • GSK Investigational Site
    • Ohio
      • Blue Ash, Ohio, Förenta staterna, 45242-5665
        • GSK Investigational Site
    • Texas
      • Tyler, Texas, Förenta staterna, 75702
        • GSK Investigational Site
    • Virginia
      • Roanoke, Virginia, Förenta staterna, 24014
        • GSK Investigational Site
      • Athens, Grekland, 11528
        • GSK Investigational Site
      • Thessaloniki, Grekland, 54007
        • GSK Investigational Site
    • East Macedonia and Thrace
      • Alexandroupoli, East Macedonia and Thrace, Grekland, 681 00
        • GSK Investigational Site
      • Jerusalem, Israel, 91120
        • GSK Investigational Site
      • Kfar Saba, Israel, 44281
        • GSK Investigational Site
      • Ramat Gan, Israel, 52621
        • GSK Investigational Site
      • Tel Aviv, Israel, 64239
        • GSK Investigational Site
      • Bergamo, Italien, 24127
        • GSK Investigational Site
      • Bologna, Italien, 40138
        • GSK Investigational Site
      • Brescia, Italien, 25123
        • GSK Investigational Site
      • Catania, Italien, 95123
        • GSK Investigational Site
      • Meldola FC, Italien, 47014
        • GSK Investigational Site
      • Milan, Italien, 20133
        • GSK Investigational Site
      • Ravenna, Italien, 48121
        • GSK Investigational Site
      • Roma, Italien, 00168
        • GSK Investigational Site
      • Siena, Italien, 53100
        • GSK Investigational Site
      • Torino, Italien, 10126
        • GSK Investigational Site
      • Aichi, Japan, 467-8602
        • GSK Investigational Site
      • Aichi, Japan, 441-8570
        • GSK Investigational Site
      • Aomori, Japan, 030-8553
        • GSK Investigational Site
      • Ehime, Japan, 790-8524
        • GSK Investigational Site
      • Fukuoka, Japan, 806-8501
        • GSK Investigational Site
      • Fukuoka, Japan, 807-8555
        • GSK Investigational Site
      • Fukuoka, Japan, 810-8563
        • GSK Investigational Site
      • Fukuoka, Japan, 815-8555
        • GSK Investigational Site
      • Gifu, Japan, 503-8502
        • GSK Investigational Site
      • Gunma, Japan, 377-0280
        • GSK Investigational Site
      • Hyōgo, Japan, 670-8540
        • GSK Investigational Site
      • Kanagawa, Japan, 247-8533
        • GSK Investigational Site
      • Kanagawa, Japan, 221-0855
        • GSK Investigational Site
      • Kochi, Japan, 781-8555
        • GSK Investigational Site
      • Nagano, Japan, 392-8510
        • GSK Investigational Site
      • Okayama, Japan, 701-1192
        • GSK Investigational Site
      • Osaka, Japan, 545-8586
        • GSK Investigational Site
      • Osaka, Japan, 530-0012
        • GSK Investigational Site
      • Shizuoka, Japan, 411-8777
        • GSK Investigational Site
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 1Z2
        • GSK Investigational Site
    • Ontario
      • London, Ontario, Kanada, N6A 5W9
        • GSK Investigational Site
      • Toronto, Ontario, Kanada, M4N 3M5
        • GSK Investigational Site
    • Quebec
      • Montreal, Quebec, Kanada, H4J 1C5
        • GSK Investigational Site
      • Beijing, Kina, 100191
        • GSK Investigational Site
      • Beijing, Kina, 100020
        • GSK Investigational Site
      • Changchun, Kina, 130012
        • GSK Investigational Site
      • Guangzhou, Kina, 510060
        • GSK Investigational Site
      • Guangzhou, Kina, 510515
        • GSK Investigational Site
      • Hangzhou, Kina, 310003
        • GSK Investigational Site
      • Jinan, Kina, 250012
        • GSK Investigational Site
      • Nanjing, Kina, 210008
        • GSK Investigational Site
      • Shenyang, Kina, 110001
        • GSK Investigational Site
      • Suzhou, Kina, 215006
        • GSK Investigational Site
      • Tianjin, Kina, 300020
        • GSK Investigational Site
      • Zhengzhou, Kina, 450052
        • GSK Investigational Site
      • Groningen, Nederländerna, 9713 GZ
        • GSK Investigational Site
    • South Holland
      • Dordrecht, South Holland, Nederländerna, 3318 AT
        • GSK Investigational Site
      • Christchurch, Nya Zeeland, 8011
        • GSK Investigational Site
      • Dunedin, Nya Zeeland, 9054
        • GSK Investigational Site
      • Takapuna Auckland, Nya Zeeland, 1309
        • GSK Investigational Site
      • Wellington, Nya Zeeland, 6021
        • GSK Investigational Site
      • Chorzów, Polen, 41-500
        • GSK Investigational Site
      • Krakow, Polen, 30510
        • GSK Investigational Site
      • Lodz, Polen, 93-513
        • GSK Investigational Site
      • Lublin, Polen, 20-081
        • GSK Investigational Site
      • Lublin, Polen, 20-090
        • GSK Investigational Site
      • Nowy Sącz, Polen, 33-300
        • GSK Investigational Site
      • Poznan, Polen, 60-569
        • GSK Investigational Site
      • Warsaw, Polen, 02-781
        • GSK Investigational Site
      • Moscow, Ryssland, 125284
        • GSK Investigational Site
      • Nizhny Novgorod, Ryssland, 603126
        • GSK Investigational Site
      • Novosibirsk, Ryssland, 630087
        • GSK Investigational Site
      • Saint Petersburg, Ryssland, 191024
        • GSK Investigational Site
      • Saint Petersburg, Ryssland, 197 089
        • GSK Investigational Site
      • Samara, Ryssland, 443021
        • GSK Investigational Site
      • Saratov, Ryssland, 410028
        • GSK Investigational Site
      • Ufa, Ryssland, 450083
        • GSK Investigational Site
      • Barcelona, Spanien, 08035
        • GSK Investigational Site
      • Barcelona, Spanien, 08916
        • GSK Investigational Site
      • Cáceres, Spanien, 10003
        • GSK Investigational Site
      • Gijón, Spanien, 33394
        • GSK Investigational Site
      • L'Hospitalet de Llobrega, Spanien, 08908
        • GSK Investigational Site
      • MOstoles Madrid, Spanien, 28933
        • GSK Investigational Site
      • Madrid, Spanien, 28007
        • GSK Investigational Site
      • Madrid, Spanien, 31008
        • GSK Investigational Site
      • Murcia, Spanien, 30008
        • GSK Investigational Site
      • PamplonaNavarra, Spanien, 31008
        • GSK Investigational Site
      • Pozuelo de AlarcOn Madr, Spanien, 28223
        • GSK Investigational Site
      • Salamanca, Spanien, 37007
        • GSK Investigational Site
      • Bournemouth, Storbritannien, BH7 7DW
        • GSK Investigational Site
      • Cardiff, Storbritannien, CF14 4XW
        • GSK Investigational Site
      • Dundee, Storbritannien, DD1 9SY
        • GSK Investigational Site
      • Leicester, Storbritannien, LE1 5WW
        • GSK Investigational Site
      • London, Storbritannien, W12 0NN
        • GSK Investigational Site
      • Stoke-on-Trent, Storbritannien, ST4 6QG
        • GSK Investigational Site
      • Sutton, Storbritannien, SM2 5PT
        • GSK Investigational Site
      • Pusan, Sydkorea, 49241
        • GSK Investigational Site
      • Seongnam-si Gyeonggi-do, Sydkorea, 13620
        • GSK Investigational Site
      • Seoul, Sydkorea, 06351
        • GSK Investigational Site
      • Seoul, Sydkorea, 06591
        • GSK Investigational Site
      • Ulsan, Sydkorea, 44033
        • GSK Investigational Site
      • Brno, Tjeckien, 625 00
        • GSK Investigational Site
      • Hradec Králové, Tjeckien, 500 05
        • GSK Investigational Site
      • Ostrava, Tjeckien, 708 52
        • GSK Investigational Site
      • Prague, Tjeckien, 128 08
        • GSK Investigational Site
      • Cologne, Tyskland, 50937
        • GSK Investigational Site
    • Baden-Wurttemberg
      • Ulm, Baden-Wurttemberg, Tyskland, 89081
        • GSK Investigational Site
    • Bavaria
      • München, Bavaria, Tyskland, 81377
        • GSK Investigational Site
      • Würzburg, Bavaria, Tyskland, 97080
        • GSK Investigational Site
    • North Rhine-Westphalia
      • Düsseldorf, North Rhine-Westphalia, Tyskland, 40225
        • GSK Investigational Site
    • Thuringia
      • Jena, Thuringia, Tyskland, 07747
        • GSK Investigational Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.

  • Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

  • Must have at least 1 aspect of measurable disease, defined as one of the following;

    1. Urine M-protein excretion >=200 mg per 24-hour, or
    2. Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or
    3. Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (<0.26 or >1.65).
  • All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] version 5.0) must be <=Grade 1 at the time of enrollment, except for alopecia.

  • Adequate organ function

Exclusion Criteria:

  • Intolerant to daratumumab.
  • Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).
  • Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.
  • Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
  • Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.
  • Prior allogenic stem cell transplant.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies.
  • Corneal epithelial disease.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Belantamab mafodotin och Bortezomib plus dexametason (arm A)

Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate

Proteasome Inhibitor

Synthetic glucocorticoid with anti-tumor activity

Aktiv komparator: Daratumumab och Bortezomib plus dexametason (arm B)

Proteasome Inhibitor

Synthetic glucocorticoid with anti-tumor activity

Anti-cluster of differentiation 38 [CD-38] monoclonal antibody

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Progression-free Survival (PFS)
Tidsram: Up to approximately 41 months

PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of >=25% from lowest value in >=1 of following (serum M-protein [absolute increase >=0.5 grams per deciliter {g/dL}]; serum M-protein increase >=1g/dL [when lowest M-protein >=5g/dL]; urine M-protein [absolute increase >=200 milligrams per 24 hours {mg/24h}]; participants without measurable serum & urine M-protein levels, difference between involved & uninvolved serum free light chains (sFLC) levels [absolute increase >10mg/dL]; appearance of new lesion,>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of >1 lesion, or >=50% increase in longest diameter of previous lesion >1 centimeter (cm) in short axis.

Up to approximately 41 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Antal deltagare med onormala ögonfynd vid oftalmisk undersökning
Tidsram: Upp till 73 månader
Upp till 73 månader
Complete Response Rate (CRR)
Tidsram: Up to 73 months

CRR is defined as percentage of participants with a confirmed complete response or better.

Up to 73 months
Overall Response Rate (ORR)
Tidsram: Up to 73 months

ORR is defined as percentage of participants with a confirmed partial response or better.

Up to 73 months
Clinical Benefit Rate (CBR)
Tidsram: Up to 73 months

CBR is defined as percentage of participants with a confirmed minimal response (MR) or better

Up to 73 months
Duration of Response (DoR)
Tidsram: Up to 73 months

DOR is defined as time from first documented evidence of partial response or better until first documented progression or death, whichever occurs first.

Up to 73 months
Time to Response (TTR)
Tidsram: Up to 73 months

TTR is defined as time from the date of randomization and the first documented evidence of response (PR or better) among participants who achieve partial response or better.

Up to 73 months
Time to Progression (TTP)
Tidsram: Up to 73 months

TTP is defined as time from the date of randomization until the earliest date of documented date of disease progression or death, whichever occurs first.

Up to 73 months
Overall Survival (OS)
Tidsram: Up to 73 months

OS is defined as time from the date of randomization until the date of death due to any cause.

Up to 73 months
Progression-free Survival on Subsequent Line of Therapy (PFS2)
Tidsram: Up to 73 months

Progression-free survival on subsequent line of therapy is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever occurs first. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier.

Up to 73 months
Minimal Residual Disease (MRD) Negativity Rate
Tidsram: Up to 73 months

Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative status by next generation sequencing (NGS).

Up to 73 months
Number of Participants With Adverse Events (AEs)
Tidsram: Up to 73 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.

Up to 73 months
Number of Participants With Clinically Significant Changes in Hematology Parameters
Tidsram: Up to 73 months

Blood samples will be collected for the analysis of hematology parameters.

Up to 73 months
Number of Participants With Clinically Significant Changes in Clinical Chemistry
Tidsram: Up to 73 months

Blood samples will be collected for the analysis of clinical chemistry parameters.

Up to 73 months
Number of Participants With Clinically Significant Changes in Urine Dipstick
Tidsram: Up to 73 months

Urine samples will be collected for the urine dipstick analysis.

Up to 73 months
Plasma Concentrations of Belantamab Mafodotin (Total Antibody) at Indicated Time Points
Tidsram: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Plasma Concentrations of Belantamab Mafodotin (ADC) at Indicated Time Points
Tidsram: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) at Indicated Time Points
Tidsram: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Tidsram: Up to 73 months

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers.

Up to 73 months
Titers of ADAs Against Belantamab Mafodotin
Tidsram: Up to 73 months

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further to be characterized for antibody titers.

Up to 73 months
Number of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)
Tidsram: Up to 73 months

The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE.

Up to 73 months
Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by EuropeanOrganization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)
Tidsram: Up to 73 months

The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning [PF], role functioning [RF], cognitive functioning [CF], emotional functioning [EF] and social functioning [SF]), three symptom scales (fatigue, pain and nausea/vomiting [N/V]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss [AL] and financial difficulties [FD]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Up to 73 months
Change From Baseline in HRQoL as Measured by EORTC IL52
Tidsram: Up to 73 months

The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score represents a high/healthy level of functioning.

Up to 73 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Studierektor: GSK Clinical Trials, GlaxoSmithKline

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

7 maj 2020

Primärt slutförande (Faktisk)

2 oktober 2023

Avslutad studie (Beräknad)

8 oktober 2029

Studieregistreringsdatum

Först inskickad

27 januari 2020

Först inskickad som uppfyllde QC-kriterierna

27 januari 2020

Första postat (Faktisk)

29 januari 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

13 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

29 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera